<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01953406</url>
  </required_header>
  <id_info>
    <org_study_id>LUNG M_FM</org_study_id>
    <nct_id>NCT01953406</nct_id>
  </id_info>
  <brief_title>The Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma</brief_title>
  <official_title>Phase II Study Evaluating the Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma Who Had Progressive Disease With Sorafenib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy of 5-fluorouracil + Mitomycin for the&#xD;
      patients with pulmonary metastasis of hepatocellular carcinoma who had progressive disease&#xD;
      with sorafenib.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Extrahepatic metastasis of hepatocellular carcinoma has recently been paradoxically&#xD;
      increasing due to increased survival with effective locoregional therapies. Sorafenib is the&#xD;
      first systemic agent that has demonstrated a significant survival benefit in patients with&#xD;
      advanced HCC; however, the modest improvement of 3 months is far from satisfactory. There is&#xD;
      no convincing evidence, to date, that systemic chemotherapy when tumor progresses after&#xD;
      sorafenib therapy improves overall survival. The combination of anticancer agents is&#xD;
      important to achieve favourable clinical results. For patients with metastatic liver cancer&#xD;
      or HCC, some studies have discussed the effectiveness of 5-fluorouracil/mitomycin(FM).&#xD;
      However, few studies have examined the actual FM regimen for HCC.&#xD;
&#xD;
      The aim of this study is to evaluate the efficacy of 5-fluorouracil/mitomycin for the&#xD;
      patients with pulmonary metastasis of hepatocellular carcinoma who had progressive disease&#xD;
      with sorafenib.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No participants were enrolled. Therefore, we stop this study, prematurely.&#xD;
  </why_stopped>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-to-progression(TTP)of lung metastasis</measure>
    <time_frame>every 12 weeks, up to 36 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>every 12 weeks, up to 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rates(CR + PR)of lung metastasis</measure>
    <time_frame>every 12 weeks, up to 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>every 12 weeks, up to 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence of intrahepatic tumor</measure>
    <time_frame>every 12 weeks, up to 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rates (CR + PR + SD)of lung metastasis</measure>
    <time_frame>every 12 weeks, up to 36 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events</measure>
    <time_frame>every 12 weeks, up to 36 weeks</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Lung Metastasis</condition>
  <arm_group>
    <arm_group_label>The 5-fluorouracil/mitomycin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Systemic chemotherapy with 5-fluorouracil/mitomycin 5-fluorouracin 15mg/kg/day D1-6 civ + Mitomycin 4mg/day iv push D1,4 till progression, every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <description>5-fluorouracin 15mg/kg/day D1-6 civ till progression, every 4 weeks</description>
    <arm_group_label>The 5-fluorouracil/mitomycin group</arm_group_label>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin</intervention_name>
    <description>Mitomycin 4mg/day iv push D1,4 till progression, every 4 weeks</description>
    <arm_group_label>The 5-fluorouracil/mitomycin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who have received previous local therapy treatments for the intrahepatic&#xD;
             hepatocellular carcinoma (RFA, PEI, cryoablation, surgery, resection) and who don't&#xD;
             have any viable intrahepatic tumor within 3 months of imaging (dynamic liver CT or&#xD;
             liver MRI) after the locoregional therapy&#xD;
&#xD;
          -  Patients who have measurable lung metastasis&#xD;
&#xD;
          -  Patients who have received their last dose of sorafenib more than 14 days before and&#xD;
             who had progressive disease of lung metastasis with sorafenib&#xD;
&#xD;
          -  Patients who have risk factors of hepatocellular carcinoma (chronic hepatitis B,&#xD;
             chronic hepatitis C, liver cirrhosis)&#xD;
&#xD;
          -  Age : 18 years to 80 years&#xD;
&#xD;
          -  ECOG Performance Status of 0 to 2&#xD;
&#xD;
          -  Child-Pugh class A,B (Child-Pugh score 5-9)&#xD;
&#xD;
          -  Adequate bone marrow, liver function as assessed by the following laboratory&#xD;
             requirements to be conducted within 7 days prior to screening:&#xD;
&#xD;
               -  WBC count &gt; 1,000/mm3&#xD;
&#xD;
               -  Absolute neutrophil count &gt; 500/mm3&#xD;
&#xD;
               -  Hb &gt; 7.0 g/dL&#xD;
&#xD;
               -  Platelet count &gt; 50,000 /mm3&#xD;
&#xD;
               -  Bilirubin &lt; 3 mg/dL&#xD;
&#xD;
               -  Adequate clotting function: INR &lt; 2.3 or &lt; 6sec&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Child-Pugh score &gt; 10&#xD;
&#xD;
          -  ECOG Performance Status &gt; 3&#xD;
&#xD;
          -  History of organ allograft&#xD;
&#xD;
          -  Patients with uncontrolled co-morbidity which needs treatment&#xD;
&#xD;
          -  Patients who have received prior systemic chemotherapy except sorafenib&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jung-Hwan Yoon, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>September 21, 2013</study_first_submitted>
  <study_first_submitted_qc>September 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2013</study_first_posted>
  <last_update_submitted>April 26, 2016</last_update_submitted>
  <last_update_submitted_qc>April 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jung-Hwan Yoon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>lung metastasis</keyword>
  <keyword>5-fluorouracil/mitomycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

